■宫颈癌幸存者可以经历阴道长度缩短,阴道狭窄,阴道弹性恶化,性频率降低和性功能障碍。这个未来,不受控制,单中心临床介入研究旨在评估阴道扩张治疗对未及时接受阴道扩张的宫颈癌幸存者阴道状况和性功能的影响。
■共有139名患者完成了研究。他们接受了6个月的阴道扩张治疗。我们评估了他们的阴道弹性,阴道直径,阴道扩张治疗前后的阴道长度和性功能。他们的阴道状况通过定制的阴道模具进行评估,以女性性功能指数评价性功能。使用SPSS25软件对所有数据进行分析。
■年龄,诊断前阴道直径和性交频率与癌症治疗后女性性功能障碍显著相关。阴道扩张治疗改善阴道狭窄,所有患者的阴道长度和性功能;然而,阴道弹性和性功能障碍的发生率没有明显改善.诊断前的性交频率,阴道弹性,末次治疗的时间间隔和治疗方式与阴道扩张治疗前后女性性功能指数评分的变化显著相关.末次治疗间隔时间少于24个月的患者或阴道弹性中等或良好的患者,从阴道扩张治疗中获益更多。
■未及时接受阴道扩张的宫颈癌幸存者仍可从阴道扩张治疗中受益,不管他们接受的治疗方法如何。此外,宫颈癌治疗后应尽早进行阴道扩张治疗.
宫颈癌幸存者在治疗后可能会出现阴道病情恶化和性功能障碍。阴道扩张可以帮助改善阴道狭窄,这些患者的阴道长度和性功能。然而,中国的一些医疗机构没有为这一人群提供及时的阴道扩张。本研究旨在探讨阴道扩张对未及时接受阴道扩张的宫颈癌幸存者是否仍然有效。结果显示,这些患者仍然受益于阴道扩张,不管他们接受的治疗方法如何。末次治疗间隔时间少于24个月的患者或阴道弹性中等或良好的患者,从阴道扩张中受益更多。这项研究的结果表明,发展中国家应该在临床实践中更多地关注宫颈癌幸存者的性问题,治疗后应及时进行阴道扩张治疗。
UNASSIGNED: Cervical cancer survivors can experience vaginal length shortening, vaginal stenosis, vaginal elasticity deterioration, sexual frequency reduction and sexual dysfunction. This prospective, uncontrolled, monocentric clinical interventional study aimed to evaluate the effect of vaginal dilation therapy on vaginal condition and sexual function of cervical cancer survivors who had not received timely vaginal dilation.
UNASSIGNED: A total of 139 patients completed the study. They received 6 months of vaginal dilation therapy. We evaluated their vaginal elasticity, vaginal diameter, vaginal length and sexual function before and after vaginal dilation therapy. Their vaginal conditions were evaluated by customised vaginal moulds, and the sexual function was assessed by female sexual function index. The SPSS 25 software was used to analyse all the data.
UNASSIGNED: Age, vaginal diameter and sexual intercourse frequency before diagnosis were significantly associated with female sexual dysfunction of the patients after cancer treatment. Vaginal dilation therapy improved vaginal stenosis, vaginal length and sexual function in all the patients; however, the vaginal elasticity and incidence of sexual dysfunction did not improve significantly. Sexual intercourse frequency before diagnosis, vaginal elasticity, time interval from last treatment and treatment modalities were significantly associated with the change in female sexual function index score before and after vaginal dilation therapy. Patients with a time interval from the last treatment less than 24 months or those who had moderate or good vaginal elasticity, benefitted more from vaginal dilatation therapy.
UNASSIGNED: Cervical cancer survivors who had not received timely vaginal dilation still benefitted from vaginal dilation therapy, irrespective of the treatment methods they received. Moreover, vaginal dilation therapy should be performed as early as possible after cervical cancer treatment.
Cervical cancer survivors can experience vaginal condition deterioration and sexual dysfunction after treatment. Vaginal dilation can help improve vaginal stenosis, vaginal length and sexual function of these patients. However, some medical institutions in
China do not provide timely vaginal dilation for this population. This study aimed to explore whether vaginal dilation was still effective for cervical cancer survivors who had not received timely vaginal dilation. The results showed that these patients still benefitted from vaginal dilation, irrespective of the treatment methods they received. Patients with a time interval from the last treatment less than 24 months or those who had moderate or good vaginal elasticity, benefitted more from vaginal dilation. The findings of the study is an indication to developing countries that more attention should be given to sexual issue of cervical cancer survivors in clinical practice, and vaginal dilation therapy should be performed promptly after treatment.